PIRAMAL PHARMA BUYS MAJORITY STAKE IN YAPAN BIO

has acquired over 40% stake in contract development and manufacturing organisation (CDMO) Yapan Bio for Rs 76 crore. With the completion of the transaction, Piramal has become the majority shareholder with 74 per recent stake and Yapan has become a subsidiary of the company. PIRAMAL PHARMA is part of the Piramal group of companies. It has lately reported strong set of Q1FY26 numbers with topline revenue reaching Rs 2,270 crore, up by 17% from the same quarter last year. EBIDTA was reported at Rs 195 crore, up by 82% from the same quarter last year. The company remains focused on delivering sustained revenue growth and further EBITDA expansion through FY27 while staying agile amid a dynamic external environment.